Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Rational design and synthesis of selective BACE-1 inhibitorsStephen F Brady, Satendra Singh, Ming Chih Crouthamel, et al.British Journal of Pharmacology|February 8, 2021
KV 1.3 channels are novel determinants of macrophage-dependent endothelial dysfunction in angiotensin II-induced hypertension in miceMiguel A Olivencia, Marta Martínez-Casales, Diego A Peraza, et al.The Journal of Biological Chemistry|December 25, 2019
Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNav1.7Robert A Neff, Mack Flinspach, Alan Gibbs, et al.Journal of Neuroinflammation|June 28, 2017
A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activationSrikant Rangaraju, Syed Ali Raza, Andrea Pennati, et al.Toxicon : Official Journal of the International Society on Toxinology|August 27, 2011
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseasesVictor Chi, Michael W Pennington, Raymond S Norton, et al.Peptides|October 11, 2017
Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShKBankala Krishnarjuna, Christopher A MacRaild, Punnepalli Sunanda, et al.Proceedings of the National Academy of Sciences of the United States of America|January 30, 2019
The molecular evolution of feathers with direct evidence from fossilsYanhong Pan, Wenxia Zheng, Roger H Sawyer, et al.Immunity|October 7, 2008
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel blockMelanie P Matheu, Christine Beeton, Adriana Garcia, et al.Elife|December 28, 2022
Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of painPhuong T Nguyen, Hai M Nguyen, Karen M Wagner, et al.The Journal of Pharmacology and Experimental Therapeutics|May 29, 2012
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune diseaseEric J Tarcha, Victor Chi, Ernesto J Muñoz-Elías, et al.Pageof 6